Fabhalta reduced probability of development to kidney failure via 43% in APPLAUSE-IgAN study140.7% of sufferers on Fabhalta demonstrated sustained discount of protein in urine over two years1Fabhalta granted precedence overview via FDA for standard approval
Basel, March 29, 2026 – Novartis lately introduced ultimate two-year effects from the Section III APPLAUSE‑IgAN find out about of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically important, clinically significant growth in estimated glomerular filtration price (eGFR) slope, a key marker of kidney serve as, when compared with placebo1. Fabhalta persistently outperformed placebo throughout key kidney results over two years, demonstrating a slowing of illness development and the prospective to maintain kidney serve as in IgAN1.
The effects have been revealed within the New England Magazine of Medication and concurrently introduced as overdue‑breaking information on the 2026 International Congress of Nephrology (WCN).
“Persistent kidney inflammation is a hallmark of IgAN, and a key driver of disease progression, leading to ongoing kidney damage and loss of function over time,” mentioned Vlado Perkovic, MD, Professor of Medication and Provost, College of New South Wales, and Steerage Committee Co‑Chair of the APPLAUSE‑IgAN find out about. “These results are important because they show that Fabhalta can reduce the risk of disease progression, help preserve kidney health, and address outcomes associated with long-term disease burden.”
Key efficacy effects over two years1
Endpoint Fabhalta Placebo Impact vs. placebo Kidney serve as
(eGFR slope)
–3.10 mL/min/1.73 m²/12 months
–6.12 mL/min/1.73 m²/12 months
3.02 mL/min/1.73 m2/12 months (49.3% slower decline)
Composite kidney failure occasions*† 21.4% 33.5% HR 0.57 (43% decrease probability) Proteinuria†
(24-hour UPCR <1g/g)
40.7% accomplished goal
23.7% accomplished goal
—
*Composite kidney failure endpoint: attaining both sustained ≥30% decline in eGFR relative to baseline, sustained eGFR <15 mL/min/1.73 m², initiation of repairs dialysis, kidney transplant, or loss of life from kidney failure†As measured via share of sufferers
“The two-year results demonstrate that Fabhalta consistently and meaningfully slows kidney function decline in high-risk patients with IgAN,” mentioned Ruchira Glaser, MD, MS, World Head, Cardiovascular, Renal and Metabolic Building, Novartis. “This progress reflects years of focused research and supports our efforts to advance more targeted treatment options to help preserve kidney health in people living with IgAN.”
The protection profile of Fabhalta over two years used to be in keeping with earlier findings. Charges of inauspicious occasions and remedy discontinuation have been low and an identical between Fabhalta and placebo1,2.
Fabhalta won speeded up approval within the U.S. and China for proteinuria discount in adults with IgAN according to information from a prespecified intervening time research of the APPLAUSE-IgAN study2,3. The 2-year information have been submitted to the U.S. Meals and Drug Management for standard approval. Fabhalta used to be granted precedence overview according to the radical mode of motion and the energy of the information. Along Fabhalta, Novartis continues to advance its multi-asset IgAN portfolio, which additionally comprises Vanrafia® (atrasentan) and investigational compound zigakibart.
About IgANIgAN is a modern autoimmune kidney illness, with roughly 25 folks in line with million international newly recognized every year4,5. IgAN is extremely debilitating because it ends up in irritation within the small filters of the kidneys, extra protein in urine, and a gentle decline in eGFR6. As much as 50% of sufferers with chronic proteinuria growth to kidney failure inside of 10 to twenty years of analysis, steadily requiring dialysis or kidney transplantation as a part of long-term illness management5-10.
Moreover, folks dwelling with IgAN steadily face psychological and social challenges6-9. Supportive care has no longer addressed the underlying reasons of the illness and steadily fails to sluggish illness development, reinforcing the desire for extra centered treatments for IgAN7-12.
About APPLAUSE-IgANAPPLAUSE-IgAN (NCT04578834) is an international, randomized, double-blind, placebo-controlled Section III find out about comparing Fabhalta in adults with biopsy-confirmed IgAN and protracted proteinuria regardless of optimized supportive care. Sufferers have been randomized 1:1 to obtain Fabhalta or placebo and have been adopted for as much as 24 months11. The main endpoint used to be the annualized overall eGFR slope over 24 months. Key secondary endpoints incorporated time to first composite kidney failure match and adjustments in proteinuria over 9 months1.
The commonest antagonistic occasions with Fabhalta have been principally mild-to-moderate infections (corresponding to COVID-19 and higher breathing tract an infection), headache, diarrhea, and hyperlipidemia, with total antagonistic match charges related to placebo1.
About Fabhalta® (iptacopan)Fabhalta (iptacopan) is an oral Issue B inhibitor designed to selectively goal the other supplement pathway, considered one of a number of key drivers of irritation and kidney injury in IgAN4,12,13. By means of inhibiting Issue B, Fabhalta targets to cut back ongoing complement-mediated harm and sluggish illness development. Fabhalta has won regulatory approvals in a couple of complement-mediated illnesses, together with IgAN, and is being evaluated throughout a variety of uncommon kidney prerequisites.
Novartis’ dedication to kidney diseasesBuilding on a legacy of greater than 40 years that started in transplant, Novartis is on a challenge to empower breakthroughs and turn out to be care in kidney fitness, beginning with kidney prerequisites that experience important unmet want.
Traditionally, those prerequisites have had significantly much less investment and analysis, resulting in a remedy panorama in large part interested by reactive or end-stage illness control, steadily with important bodily, emotional, and monetary burdens. Our portfolio goals the underlying reasons of illness, with an intention to give protection to kidney fitness and prolong or save you dialysis and/or transplantation. Our objective is to lend a hand sufferers get again to dwelling existence on their phrases – whether or not at paintings, in class, or with family members, and via partnering with sufferers, advocates, clinicians and policymakers, we intention to boost consciousness, boost up analysis, and get sufferers the best care, quicker.
DisclaimerThis press free up incorporates forward-looking statements inside the that means of the USA Personal Securities Litigation Reform Act of 1995. Ahead-looking statements can most often be recognized via phrases corresponding to “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or an identical phrases, or via categorical or implied discussions referring to possible advertising and marketing approvals, new indications or labeling for the investigational or licensed merchandise described on this press free up, or referring to possible long term revenues from such merchandise. You will have to no longer position undue reliance on those statements. Such forward-looking statements are according to our present ideals and expectancies referring to long term occasions, and are topic to important identified and unknown dangers and uncertainties. Will have to a number of of those dangers or uncertainties materialize, or will have to underlying assumptions end up mistaken, precise effects would possibly range materially from the ones set forth within the forward-looking statements. There may also be no be sure that the investigational or licensed merchandise described on this press free up will likely be submitted or licensed on the market or for any further indications or labeling in any marketplace, or at any explicit time. Nor can there be any be sure that such merchandise will likely be commercially a hit one day. Particularly, our expectancies referring to such merchandise might be suffering from, amongst different issues, the uncertainties inherent in analysis and building, together with medical trial effects and extra research of current medical information; regulatory movements or delays or executive law most often; world tendencies towards fitness care value containment, together with executive, payor and basic public pricing and repayment pressures and necessities for greater pricing transparency; our skill to procure or care for proprietary highbrow belongings coverage; the precise prescribing personal tastes of physicians and sufferers; basic political, financial and industry prerequisites, together with the results of and efforts to mitigate pandemic illnesses; protection, high quality, information integrity or production problems; possible or precise information safety and knowledge privateness breaches, or disruptions of our knowledge era programs, and different dangers and components referred to in Novartis AG’s present Shape 20-F on document with the USA Securities and Alternate Fee. Novartis is offering the guidelines on this press free up as of this date and does no longer adopt any legal responsibility to replace any forward-looking statements contained on this press free up on account of new knowledge, long term occasions or differently.
About Novartis Novartis is an cutting edge medications corporate. On a daily basis, we paintings to reimagine medication to support and prolong folks’s lives in order that sufferers, healthcare pros and societies are empowered within the face of significant illness. Our medications succeed in greater than 300 million folks international.
Reimagine medication with us: Consult with us at https://www.novartis.com and hook up with us on LinkedIn, Fb, X/Twitter and Instagram.
References
Novartis. Knowledge on fileNovartis Prescription drugs Company. Novartis receives FDA speeded up popularity of Fabhalta® (iptacopan), the primary and solely supplement inhibitor for the discount of proteinuria in predominant IgA nephropathy (IgAN) (2024). To be had at: https://www.novartis.com/information/media-releases/novartis-receives-fda-accelerated-approval-fabhalta-iptacopan-first-and-only-complement-inhibitor-reduction-proteinuria-primary-iga-nephropathy-igan. Accessed March 2026 Novartis China. Novartis’ cutting edge medication Fabhalta® (iptacopan) licensed in China for a brand new indication. Novartis China website online (in Mandarin). To be had at: https://www.novartis.com.cn/information/nuohuazaiyingshenzangjibingzhiliaolingyulichengbeichuangxinyaowufeihedayansuanyipukepanjiaonangigashenbingshiyingzhengzaizhongguohuopi. Accessed March 2026Rizk DV, Maillard N, Julian BA, et al. The rising function of supplement proteins as a goal for treatment of IgA nephropathy. Entrance Immunol 2019;10:504.Cheung C, Barratt J. The abruptly converting remedy panorama of IgA nephropathy. Semin Nephrol. 2025;44:151573.Kwon CS, Daniele P, Forsythe A et al. A scientific literature overview of the epidemiology, health-related high quality of existence affect, and financial burden of immunoglobulin a nephropathy. J Well being Econ Results Res. 2021;8:36–45.Pitcher D, Braddon F, Hendry B et al. Lengthy-term results in IgAN. Clin J Am Soc Nephrol. 2023;18:727–8.Mohd R, Mohammad Kazmin NE, Abdul Cader R, et al. Lengthy-term consequence of immunoglobulin A (IgA) nephropathy: a unmarried heart enjoy. PLoS One. Nationwide Kidney Basis. The voice of the affected person (2020). To be had at: https://igan.org/wp-content/uploads/2021/01/VOP_IgAN_12-7-20__FNL.pdf. Accessed March 2026.Kidney Illness: Making improvements to World Results (KDIGO) Glomerular Illnesses Paintings Staff. KDIGO 2021 Medical Observe Tenet for the Control of Glomerular Illnesses. Kidney Int. 2021;100:S1–276.Clinicaltrials.gov. NCT04578834. Find out about of Efficacy and Protection of LNP023 in Number one IgA Nephropathy Sufferers (APPLAUSE-IgAN). To be had at: https://clinicaltrials.gov/find out about/NCT04578834. Accessed March 2026.Perkovic V, Barratt J, Rovin B, et al. Choice supplement pathway inhibition with iptacopan in IgA nephropathy. N Engl J Med. 2025;392:531–543.Chiu YL, Lin WC, Shu KH, et al. Choice supplement pathway is activated and related to galactose-deficient IgA(1) antibody in IgA nephropathy sufferers. Entrance Immunol 2021;12:638309.
# # #
